Dusetzina SB, et al. - In this investigation, researchers evaluated point-of-sale prices for orally administered anticancer drugs offered through Medicare Part D from 2010 to 2018 and estimated how out-of-pocket spending changed from 2010 to 2019 as a result of declining coinsurance as part of the Part D coverage gap closed. The Affordable Care Act has gradually reduced the required coinsurance for branded drugs in the coverage gap (ie, doughnut hole) from 100% in 2010 to 25% in 2019 to improve affordability of drugs for patients. Price increases over the same period, however, could have offset expected savings for patients requiring specialty drugs, including anticancer drugs.